B cell reductive therapy in the treatment of autoimmune diseases: A focus on monoclonal antibody treatment of rheumatoid arthritis

Joseph Tuscano, Shiloh Martin, Kyle Song, Theodore Wun

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

The therapeutic approach to patients with autoimmune disorders is in the midst of a dramatic change. Monoclonal antibody technology has allowed us to dissect and now manipulate the human immune system with greater precision. It is now widely recognized that B lymphocytes play a role in the pathogenesis of many autoimmune diseases, though the extent and contribution is a matter of debate and active investigation. There is emerging data to suggest that both antibody-dependent and independent mechanisms contribute to disease pathogenesis. However, given the heterogeneous nature of autoimmune diseases, and the varied responses to B lymphocyte reduction, the role of B lymphocytes is likely disease-specific. The two clinical trials discussed in this review demonstrate remarkable consistency in the ability of B cell reduction to ameliorate the clinical manifestations of rheumatoid arthritis with minimal toxicity. B lymphocyte targeted approaches to autoimmune disease in general, and RA specifically, will not only provide an effective and potentially less toxic alternative treatment option, but also allow for a better understanding of the pathogenesis of these complex and morbid diseases.

Original languageEnglish (US)
Pages (from-to)521-527
Number of pages7
JournalHematology
Volume10
Issue number6
DOIs
StatePublished - Dec 2005

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'B cell reductive therapy in the treatment of autoimmune diseases: A focus on monoclonal antibody treatment of rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this